StockUS listing USSBMJFPINKHealthcareQuality Compounder

Dimerix Ltd(SBMJF) Stock Analysis | Healthcare

USD --+0.00%
Reward57Moderate
Risk19Low
75%Data
Revenue growing 1831% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 210.14M
Reward Ratingⓘ57 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ19 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on SBMJF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Dimerix Ltd?

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.

AI Brief Pro

The brief on Dimerix Ltd

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Dimerix Ltd?

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 210.14M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (57)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap210.14M
Beta0.223
Insider Activity
12M windowNo data
No insider activity data available for this ticker.